Registration Fee

Questions? Call 503-582-9055 or email info@oregonpharmacy.org

ACPE Continuing Pharmacy Education

This program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon State Pharmacy Association (OSPA). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 30 days of program attendance.

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 30 days of program attendance to ensure awarding of credit. It is the participant’s responsibility to check CPE Monitor and ensure credits have successfully uploaded.

Target Audience: Pharmacists and Pharmacy Technicians

Total Credits Available: 15 1-hour activities for up to 1.5 CEUs

Activity Type(s): Knowledge and Application-based

Conflict of Interest Disclosures: Dr. Ben Kong is a consultant for Clarified Precision Medicine. This relationship has been mitigated for this program. All other speakers and planners for this program have no financial relationships with ineligible companies to disclose.

 

Title: End HIV Oregon

UAN: 0036-9999-23-101-L02-P/T

Date & Time: 2/25/23 at 8:00 am

Speakers: Geoff L’Heureux, PharmD, AAHIVP

Activity-Topic: HIV/AIDS

Learning Objectives:

1. (RPh) Define the protocols OBOP has approved for pharmacist prescribing of HIV PrEP and PEP
2. (RPh) Discuss the mechanism of action of antiretrovirals in the lifecycle of the HIV virus and how they prevent HIV
3. (RPh) Examine use of protocol documents and unique features of each
4. (RPh)Review the highlights of HIV pharmacist prevention protocols
5. (CPT) Recognize protocols for HIV PrEP and PEP
6. (CPT) Explain how to candidly but discretely screen who needs what protocol candidly
7. (CPT) List drugs used for HIV PrEP and PEP

 

Title: NCPA Update: Federal Advocacy, FTC, State Enforcement, and Legal

UAN: 0036-9999-23-102-L03-P/T

Date & Time: 2/25/23 at 9:00 am

Speakers: Steve Postal, JD

Activity-Topic: Law Related to Pharmacy Practice

Learning Objectives:

1. Recall major PBM introduced the affects the profession
2. Recognize developments with FTC as they affect the profession
3. List updates in Medicaid managed care reform for pharmacy

 

Title: Promoting Professional Well-Being: Is the Glass Half-Full or Half-Empty?

UAN: 0036-9999-23-103-L04-P/T

Date & Time: 2/25/23 at 10:00 am

Speakers: Anita Cleven, PharmD, RPh; Susan Morley, PharmD, MBA, MS

Activity-Topic: Pharmacy Administration

Learning Objectives:

1. List the three dimensions of burnout
2. Describe the consequences of burnout for health care professionals
3. Describe the consequences of burnout for health care organizations
4. Recognize how work system factors influence burnout

 

Title: Precision Medicine – A Primer for the Community Professional

UAN: 0036-9999-23-104-L01-P/T

Date & Time: 2/25/23 at 11:00 am

Speakers: Ben Kong, PharmD, BCPS

Activity-Topic: Disease State Management/Drug Therapy

Learning Objectives:

1. Discuss how genetic variations lead to differing responses to medication
2. Recognize resources and guidelines related to pharmacogenetics
3. (RPh) Describe how to communicate to patients about direct-to-consumer genetic reports

 

Title: COVID-19 Therapeutics: Where Are We Now?

UAN: 0036-9999-23-105-L01-P/T

Date & Time: 2/25/23 at 1:00 pm

Speakers: Andrew Gibler, PharmD, FOSHP

Activity-Topic: Disease State Management/Drug Therapy

Learning Objectives:

1. Summarize the history of FDA authorizations and approvals of COVID-19 therapeutics and identify which drugs are recommended now
2. Describe the differences between the two oral antiviral medications authorized to treat COVID-19 infection
3. Discuss the clinical evidence of benefit and harms for the two oral antivirals authorized to treat COVID-19 infection
4. Briefly review the current mechanisms for pharmacist prescribing of COVID-19 therapeutics

 

Title: Drug Supply Chain Security Act

UAN: 0036-9999-23-106-L04-P/T

Date & Time: 2/25/23 at 2:00 pm

Speakers: Penny Reher, RPh

Activity-Topic: Pharmacy Administration

Learning Objectives:

1. Recall what is not part of the core DSCSA requirements
2. List the two most important things needing to be in place to comply with DSCSA
3. (RPh) Discuss the importance of the Lanham Act and what violations of it result in consequences to pharmacists and their businesses
4. (RPh) State when in 2023 the last item in the DSCSA implementation list needs to be in place
5. (RPh) Identify the likely reasons to suspect a product is illegitimate
6. (CPT) State when item level tracing as well as electronic interoperable tracing system needs to be in place
7. (CPT) Discuss what changes will happen after November 2023 regarding transaction history logs

 

Title: 340B Panel Discussion

UAN: 0036-9999-23-107-L04-P/T

Date & Time: 2/25/23 at 3:00 pm

Speakers: Amy Cervan, PharmD; Marty Carty, Government Affairs Director: Trevor Douglass, DC, MPH

Activity-Topic: Pharmacy Administration

Learning Objectives:

1. Describe the 340B program, who is eligible and how to participate
2. Define Covered Entity
3. Describe the intent of the 340B program
4. Discuss how legislature in Oregon applies the 340B program
5. Explain how entities utilize savings from 340B program to expand services in the community

 

Title: The Oregon Psilocybin Services Act: Implementation of a Legalized Framework in Oregon

UAN: 0036-9999-23-108-L03-P/T

Date & Time: 2/25/23 at 4:00 pm

Speakers: Angela Allbee, MPA

Activity-Topic: Law Related to Pharmacy Practice

Learning Objectives:

1. (RPh) Recall the statutory criteria for accessing psilocybin services in Oregon, the three components of psilocybin services, and the product chain of custody for psilocybin products pursuant to ORS 475A, the Oregon Psilocybin Services Act
2. (RPh) Demonstrate awareness of how a non-directive approach to psilocybin services creates a clear separation between ORS 475A licensure and other professional license types in Oregon
3. (RPh) Use the knowledge of ORS 475A to differentiate between decriminalization and legalization, between the statutory oversight of OHA and local and state law enforcement, and between the regulated and unregulated aspects of the psilocybin ecosystem in Oregon
4. (CPT) List the five priorities of Healthier Together Oregon, the State Health Improvement Plan for 2020-2024, and the ways that psilocybin services in Oregon may align with these priorities
5. (CPT) Demonstrate awareness of the statutory criteria that facilitators must meet to be licensed under ORS 475A and how licensed facilitators may contribute to reducing health inequities in Oregon
6. (CPT) Employ cultural sensitivity and awareness regarding the history of psilocybin and the impact that the War on Drugs had on communities of color

 

Title: Patient Safety – Harm Reduction (Naloxone Work Group)

UAN: 0036-9999-23-109-L05-P/T

Date & Time: 2/26/23 at 8:00 am

Speakers: Dane Zahner, Prevention Manager, HIV Alliance; Korin Richardson, PharmD, BCPP

Activity-Topic: Patient Safety

Learning Objectives:

1. Describe behaviors to utilize when helping patients with substance use disorders (SUD)
2. Provide patients information on relevant resources related to harm reduction
3. Share relevant resources with individual patients with substance use disorders to improve their safety

 

Title: Patients in Crisis: Suicide Prevention, Intimate Partner Violence, and Pharmacy in the VA

UAN: 0036-9999-23-110-L05-P/T

Date & Time: 2/26/23 at 9:00 am

Speakers: Julie Borovik, MA, LMFT; Heather Jenard, LCSW; Korin Richardson, PharmD, BCPP

Activity-Topic: Patient Safety

Learning Objectives:

1. Recall the acronym SAVE
2. Demonstrate confidence when helping patients with acute depression, anxiety, or substance use disorders
3. Provide patients information on relevant resources when in crisis
4. (RPh) Apply relevant guidelines and resources to individual patients in crisis to improve their safety
5. (CPT) Share relevant resources to individual patients in crisis to improve their safety or address their life stressors

 

Title: Talks on Mpox

UAN: 0036-9999-23-111-L01-P/T

Date & Time: 2/26/23 at 10:00 am

Speakers: Jen Stanislaw, PharmD, BCACP

Activity-Topic: Disease State Management/Drug Therapy

Learning Objectives:

1. Describe the Mpox case trends, broken down by geography and patient demographics
2. Recognize the common signs, symptoms, and routes of transmission of an Mpox infection
3. Identify prophylaxis options for an Mpox infection
4. (RPh only) Create a care plan for those at high risk, or exposed to Mpox

 

Title: Hacked! Securing Your Pharmacy Data and Handling the Breach

UAN: 0036-9999-23-112-L04-P/T

Date & Time: 2/26/23 at 11:00 am

Speakers: Paige Clark, RPh; Brad Gallagher

Activity-Topic: Pharmacy Administration

Learning Objectives:

1. Evaluate whether the pharmacy’s current data security policies and procedures meet best practice
2. Evaluate the level of risk the pharmacy is exposed to for a data breach, and how to evaluate if the technology offers enough security to protect data
3. Describe the steps to plan for a breach event and its aftermath

 

Title: New Drug Update

UAN: 0036-9999-23-113-L01-P/T

Date & Time: 2/26/23 at 1:00 pm

Speakers: Natalea Braden-Suchy, PharmD, BCACP

Activity-Topic: Disease State Management/Drug Therapy

Learning Objectives:

1. Discuss new pharmacotherapy choices
2. Describe indications, mechanism of action, common adverse effects, and significant drug interactions for those products
3. Highlight safety concerns with selected new choices
4. Compare selected new choices with established therapies

 

Title: Fostering an Inclusive Climate in Pharmacy

UAN: 0036-9999-23-114-L04-P/T

Date & Time: 2/26/23 at 2:00 pm

Speakers: Aleksandra Sikora, PhD

Activity-Topic: Additional Topics

Learning Objectives:

1. Recognize social identity categories
2. Describe importance of diversity
3. Explain inclusion framework
4. Examine implicit bias
5. Analyze inclusion elements for your organization

 

Title: Professional Identity Formation: The Importance of Mindset and Emotional Intelligence

UAN: 0036-9999-23-115-L99-P/T

Date & Time: 2/26/23 at 3:00 pm

Speakers: Anita Cleven, PharmD; Susan Morley, PharmD, MBA, MS

Activity-Topic: Additional Topics

Learning Objectives:

1. Define identity
2. Define Professional Identity Formation
3. Discuss two interrelated concepts; mindset and emotional intelligence and its relevance to Professional Identity Formation
4. Identify tips to help a learner cultivate their professional identities